glp 1 drugs in development GLP-1 2.0: Where the Next Wave of Value Will Be Created FORMULATION DEVELOPMENT - Innovative Drug

Intravenous (IV) Injections IV therapy delivers glutathione directly into the vein, bypassing the digestive system entirely

When any antioxidant, including glutathione, retains all its electrons (making the number of protons and electrons in the molecule equal), it is in a reduced state

Standard cycle structure: On cycle: 8-12 weeks of daily dosing Off cycle: 4 weeks without GHRP-6 (Mod GRF 1-29 can be continued during off-cycle if desired) Repeat Some researchers run longer cycles of 16-20 weeks, particularly when GHRP-6 is part of a structured peptide cycle

The primary endpoint, change of weight loss over time, was analyzed by repeated-measures ANOVA comparing patients with GLP-1-RAs plus usual care weight management (GLP-1-RA group) to patients with usual care weight management only (UCWM)

[Abstract] PLoS Genet

Evidence Comparison by Route The bottom line: topical GHK-Cu has human-grade evidence for skin outcomes